Michael Ibrahim

Michael Ibrahim

Auto-generated profile, based on publicly available information

Michael Ibrahim

Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2012 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
MNManoraj Navaratnarajah
Manoraj Navaratnarajah
MIMichael Ibrahim
Michael Ibrahim
USUrszula Siedlecka
Urszula Siedlecka
CDCarin van Doorn
Carin van Doorn
ASAdarsh Shah
Adarsh Shah
Cesare M. N. TerraccianoCesare M. N. Terracciano
Cesare M. N. Terracciano
Ivabradine (Iva) has shown beneficial structural and functional effects in clinical and experimental heart failure (HF), but its action in combination with mechanical unloading (MU), such as during treatment with left ventricular assist devices (LVAD), is unknown. The aim of this study was to investigate the effects of Iva during MU, in a rodent model of HF. We studied the chronic effects (4 weeks) of Iva (10 mg/kg/day) alone and in combination with MU [induced by heterotopic abdominal heart transplantation (HATx)] on whole-heart and cellular structure, function, and excitation–contraction (E–C) coupling in a rodent (rat) model of HF, 12 weeks post-left coronary artery (LCA) ligation. Effects of Iva were compared with those of β-blockade using metoprolol [(Met), 250 mg/kg/day]. Iva, but not Met, reversed myocardial fibrosis, alone and in combination with MU. MU-induced restoration of deranged E–C coupling was enhanced by Iva to a greater extent than Met: both Iva and Met enhanced the recovery of the Ca2+ transient amplitude and the sarcoplasmic reticulum (SR) Ca2+ content, but Iva alone maintained MU-induced normalization of L-type Ca2+ current and t-tubule abnormalities. Met prevented MU-induced reduction in the myocardial size (myocardial atrophy); Iva had no effect on this parameter. Iva shows beneficial structural and E–C coupling effects during MU: Iva reverses myocardial fibrosis and enhances the restoration of deranged E–C coupling, displaying more beneficial effects than that of Met. These results suggest that Iva may prove effective in enhancing functional recovery in heart failure patients receiving LVAD therapy.

23 July 2022 in Journal of Cardiac Surgery
Verified
Journal Article
Open access
AUAsad A. Usman
Asad A. Usman
ASAudrey E. Spelde
Audrey E. Spelde
SOSalim E. Olia
Salim E. Olia
MCMarisa Cevasco
Marisa Cevasco
CBChristian Bermudez
Christian Bermudez
JGJacob Gutsche
Jacob Gutsche

18 April 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SCShih-Shih Chen
Shih-Shih Chen
Jacqueline C. BarrientosJacqueline C. Barrientos
Jacqueline C. Barrientos
GFGerardo Ferrer
Gerardo Ferrer
MKMorgan King-Richards
Morgan King-Richards
YCYu-Ju Chen
Yu-Ju Chen
NCNicholas Chiorazzi
Nicholas Chiorazzi
Purpose: Inhibitors of Bruton's tyrosine kinase (BTKi) and PI3K (PI3Ki) have significantly improved therapy of chronic lymphocytic leukemia (CLL). However, the emergence of resistance to BTKi has introduced an unmet therapeutic need. Hence, we sought evidence for essential roles of PI3K-δi and PI3K-γi in treatment-naïve and BTKi-refractory CLL. Experimental Design: Responses to PI3K-δi, PI3K-γi, and the dual-inhibitor duvelisib in each B, T, and myeloid cell compartments of CLL were studied in vitro, and in a xenograft mouse model using primary cells from treatment-naïve and ibrutinib-resistant patients, and finally, in a patient with ibrutinib-resistant CLL treated with duvelisib. Results: We demonstrate the essential roles of PI3K-δ for CLL B-cell survival and migration, of PI3K-γ for T-cell migration and macrophage polarization, and of dual inhibition of PI3K-δ,γ for efficacious reduction of leukemia burden. We also show that samples from patients whose disease progressed on ibrutinib were responsive to duvelisib therapy in a xenograft model, irrespective of BTK mutations. In support of this, we report a patient with ibrutinib-resistant CLL, bearing a clone with BTK and PLCγ2 mutations, who responded immediately to single-agent duvelisib with redistribution lymphocytosis followed by a partial clinical remission associated with modulation of T and myeloid cells. Conclusions: Our data define the mechanism of action whereby dual inhibition of PI3K-δ,γ affects CLL B-cell numbers and T and myeloid cell pro-leukemia functions and support the use of duvelisib as a valuable approach for therapeutic interventions, including for patients refractory to BTKi.

15 May 2023
Verified
Other
Open access
SCShih-Shih Chen
Shih-Shih Chen
Jacqueline C. BarrientosJacqueline C. Barrientos
Jacqueline C. Barrientos
GFGerardo Ferrer
Gerardo Ferrer
MKMorgan King-Richards
Morgan King-Richards
YCYu-Ju Chen
Yu-Ju Chen
NCNicholas Chiorazzi
Nicholas Chiorazzi
Distinct actions of PI3K-δ and PI3K-γ on human cytokines in PDX model of U-CLL and M-CLL patients.

15 May 2023
Verified
Other
Open access
SCShih-Shih Chen
Shih-Shih Chen
Jacqueline C. BarrientosJacqueline C. Barrientos
Jacqueline C. Barrientos
GFGerardo Ferrer
Gerardo Ferrer
MKMorgan King-Richards
Morgan King-Richards
YCYu-Ju Chen
Yu-Ju Chen
NCNicholas Chiorazzi
Nicholas Chiorazzi
Effects of inhibition of PI3K isoforms on CLL-cell proliferation, survival, and migration.

15 May 2023
Verified
Other
Open access
SCShih-Shih Chen
Shih-Shih Chen
Jacqueline C. BarrientosJacqueline C. Barrientos
Jacqueline C. Barrientos
GFGerardo Ferrer
Gerardo Ferrer
MKMorgan King-Richards
Morgan King-Richards
YCYu-Ju Chen
Yu-Ju Chen
NCNicholas Chiorazzi
Nicholas Chiorazzi
IC50 values of PI3K isoform inhibitors used. Duvelisib5, IPI-3063 (PI3K-d inhibitor)5, IPI-549 (PI3K-g inhibitor used in vitro)50, IPI-5243 (PI3K-g inhibitor used in vivo).